Triapine(Triapine) - 药物靶点：RNR_在研适应症：腺鳞癌，宫颈鳞状细胞癌，鳞状细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Triapine、3-AP、NSC#663249

+ [5]

靶点

RNR

作用机制

RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)

治疗领域

癌症泌尿生殖系统疾病其他疾病+ [2]

在研适应症

腺鳞癌宫颈鳞状细胞癌鳞状细胞癌+ [10]

非在研适应症

腺泡细胞癌急性淋巴细胞白血病急性早幼粒细胞白血病+ [64]

原研机构

Nanotherapeutics, Inc.

在研机构

National Cancer Institute

Nanopharmaceutics, Inc.初创企业

Nanotherapeutics, Inc.

非在研机构

Vion Pharmaceuticals, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS号143621-35-6

关联

33

项与 Triapine 相关的临床试验

NCT06410248 / Recruiting临床1期IIT

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

开始日期2024-07-23

申办/合作机构

Northwestern University

[+2]

NCT05724108 / Recruiting临床2期IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

开始日期2023-08-30

申办/合作机构

National Cancer Institute

NCT04494113 / Recruiting早期临床1期IIT

A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma

This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.

开始日期2022-02-08

申办/合作机构

National Cancer Institute

100 项与 Triapine 相关的临床结果

登录后查看更多信息

100 项与 Triapine 相关的转化医学

登录后查看更多信息

100 项与 Triapine 相关的专利（医药）

登录后查看更多信息

308

项与 Triapine 相关的文献（医药）

2024-10-01·NEUROPEPTIDES

Bromelain decreases oxidative stress and Neuroinflammation and improves motor function in adult male rats with cerebellar Ataxia induced by 3-acetylpyridine

Article

作者: Sani, Mojtaba ; Babaei, Mohammad Reza ; Nourirad, Seyedeh Naghmeh ; Chegeni, Maryam Jahani ; Tahvildari, Azin ; Bayat, Amir-Hossein ; Lahiji, Hormoz ; Khakpour, Yaser ; Eskandari, Neda ; Roustaee, Susan ; Balaghirad, Nika ; Hashemabady, Maryam ; Aliaghaei, Abbas ; Sagharichi, Mastooreh ; Bahar, Reza ; Mehranpour, Maryam ; Fathi, Mobina ; Vakili, Kimia ; Taghizadeh, Mohammad

Bromelain is a plant-based molecule with antioxidant, antithrombotic, anticancer, and anti-inflammatory properties. Bromelain has been shown to reduce the release of inflammatory cytokines. This study aimed to determine whether bromelain can prevent ataxia in rats caused by 3-acetylpyridine (3-AP). Thirty-six albino rats were divided into the control, 3-AP, and 3-AP + Brom groups. In the 3-AP + Brom group, bromelain was injected intraperitoneally at 40 mg/kg daily for 30 days. Various techniques such as rotarod, electromyography (EMG), elevated plus maze, IHC, and Sholl analysis were used to evaluate the possible effects of bromelain on cerebellar neurons and glial cells. The results demonstrated significant improvements in most of the 3-AP + Brom, including motor coordination, neuromuscular response, anxiety, oxidative capacity, microgliosis, astrogliosis, cell death, and morphological variables compared to the 3-AP group. The mechanism of action of bromelain in restoring cerebellar ataxia needs further investigation, but it may be a candidate to help restore degeneration in animals with ataxia.

2024-10-01·MICROCHIMICA ACTA

Enhancing colorimetric efficiency: nanozyme-activated peroxymonosulfate for in situ 3-aminophenol detection

Article

作者: Dai, Hongliang ; Liu, Xingyu ; Wang, Xingang ; Qi, Jingwen ; Xiao, Rongsheng ; Li, Mingde ; Bao, Meishuo ; Yan, Dengxin ; Zhang, Wuxiang

A novel colorimetric approach specifically designed to effectively identify the presence of 3-aminophenol (3-AP) in environmental water is introduced. Briefly, a nitrogen-doped carbon-supported cobalt nanozyme (Co@CN-1) was synthesized and utilized to improve the oxidation of 3,3',5,5'-tetramethylbenzidine (TMB) in the presence of peroxymonosulfate (PMS). Comparative catalytic reactions confirmed that the performance of PMS as an activator exceeds that of hydrogen peroxide catalytically by a factor of 3.5. The catalytic reaction parameters underwent optimization, further resulting in the derivation of a linear detection equation for 3-AP, expressed as inhibition rate (IR%) = 3.35[3-AP]-4.36 (0-20 μM, R² = 0.994) and IR% = 1.43[3-AP] + 31.87 (20-36 μM, R² = 0.992), with the limit of detection (LOD) of 2.84 μM. The linear relationship between 3-AP concentration and the conversion of color to grayscale value (GSV) was established by smartphones, expressed as GSV = 1.28[3-AP] + 147.10 (R² = 0.972). Density functional theory calculations revealed that Co acts as the preferred active site for donating electrons in PMS activation. This work provides a rapid and accurate approach for monitoring 3-AP concentration, enabling real-time analysis and potentially contributing to environmental and ecological studies.

2024-08-01·CANCER LETTERS

Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor

Article

作者: Chow, Zeta ; Anthony, Lowell ; Johnson, Jeremy ; Weiss, Heidi ; Townsend, Courtney M ; Evers, B Mark ; Schrader, Jörg ; Yang, Eddy S ; Izumi, Tadahide ; Rychahou, Piotr ; Jeong, Jong Cheol ; Castle, Jennifer T ; Chauhan, Aman

Ribonucleotide Reductase (RNR) is a rate-limiting enzyme in the production of deoxyribonucleoside triphosphates (dNTPs), which are essential substrates for DNA repair after radiation damage. We explored the radiosensitization property of RNR and investigated a selective RRM2 inhibitor, 3-AP, as a radiosensitizer in the treatment of metastatic pNETs. We investigated the role of RNR subunit, RRM2, in pancreatic neuroendocrine (pNET) cells and responses to radiation in vitro. We also evaluated the selective RRM2 subunit inhibitor, 3-AP, as a radiosensitizer to treat pNET metastases in vivo. Knockdown of RNR subunits demonstrated that RRM1 and RRM2 subunits, but not p53R3, play significant roles in cell proliferation. RRM2 inhibition activated DDR pathways through phosphorylation of ATM and DNA-PK protein kinases but not ATR. RRM2 inhibition also induced Chk1 and Chk2 phosphorylation, resulting in G1/S phase cell cycle arrest. RRM2 inhibition sensitized pNET cells to radiotherapy and induced apoptosis in vitro. In vivo, we utilized pNET subcutaneous and lung metastasis models to examine the rationale for RNR-targeted therapy and 3-AP as a radiosensitizer in treating pNETs. Combination treatment significantly increased apoptosis of BON (human pNET) xenografts and significantly reduced the burden of lung metastases. Together, our results demonstrate that selective RRM2 inhibition induced radiosensitivity of metastatic pNETs both in vitro and in vivo. Therefore, treatment with the selective RRM2 inhibitor, 3-AP, is a promising radiosensitizer in the therapeutic armamentarium for metastatic pNETs.

4

项与 Triapine 相关的新闻（医药）

2024-05-14

·PRNewswire

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

临床1期寡核苷酸

2022-11-02

·PRNewswire

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 [email protected] SOURCE Nanopharmaceutics, Inc.

放射疗法

2022-11-02

·BioSpace

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the NCI Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 jtalton@nanopharmaceutics.com View original content: SOURCE Nanopharmaceutics, Inc.

放射疗法

100 项与 Triapine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺鳞癌	临床3期	美国	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	美国	National Cancer Institute	2016-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 ... 更多	450	Intensity-Modulated Radiation Therapy+Cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	膚鹹衊繭淵簾窪壓壓膚(繭鹹鬱淵壓簾顧衊淵網) = 膚選鹽膚衊餘積鹽鑰襯鹹簾醖蓋窪鹹遞鑰鬱膚 (壓顧鑰襯糧鹽餘窪鏇積, 鬱蓋鑰艱觸遞願網窪繭 ~ 顧鹽觸製齋艱顧鏇簾製) 更多	-	2024-01-05
				Intensity-Modulated Radiation Therapy+Triapine+Cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	膚鹹衊繭淵簾窪壓壓膚(繭鹹鬱淵壓簾顧衊淵網) = 憲夢憲製鑰構構淵餘網鹹簾醖蓋窪鹹遞鑰鬱膚 (壓顧鑰襯糧鹽餘窪鏇積, 鬱網鏇淵衊鹽廠衊蓋觸 ~ 鏇襯獵構艱鑰簾範糧鬱) 更多
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT	廠鏇衊衊夢選蓋齋願憲(窪膚淵醖獵鹹獵選夢夢): HR = 1.018 (95% CI, 0.634 ~ 1.635) 更多	不佳	2023-05-31
				Cisplatin + RT + Triapine
NCT04234568 (AACR2023) 人工标引	临床1期	胃肠胰神经内分泌肿瘤 SSTR Expression	31	triapine+Lutetium Dotatate LU-177	糧積鏇鹽夢選窪製繭憲(襯廠鹽範顧遞壓膚衊鏇) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. 鬱鑰簾蓋鑰醖夢膚構繭 (觸夢艱遞艱醖艱窪艱選 ) 更多	积极	2023-04-14
NCT04234568 (ASCO_GI2023) 人工标引	临床1期	SSTR阳性胃肠胰神经内分泌肿瘤 SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	顧鬱選壓構夢觸醖顧鏇(觸築遞淵選構範鏇廠糧) = 願鹽鑰繭醖鏇憲製鹹鹽遞齋願艱繭製獵築鹹鏇 (遞襯壓願窪廠遞範醖築 ) 更多	积极	2023-01-24
04234568 (ASCO2020)	临床1期	神经内分泌肿瘤一线	29	Triapine and Lutetium Lu 177 Dotatate	齋壓選顧膚窪鬱衊廠衊(鬱醖夢簾淵製襯鑰齋簾) = 夢簾衊窪醖鏇衊積願遞積鏇壓蓋積鏇積壓製窪 (夢襯製齋顧鹽壓繭選鏇 )	-	2020-05-25
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy+triapine	膚獵夢壓範範觸獵衊範(廠鹹廠夢簾範淵襯糧醖) = 艱鬱遞齋鏇窪構衊膚繭簾構膚齋壓網製顧顧範 (獵衊願蓋繭鬱衊願鹹醖 ) 更多	积极	2019-10-15
				cisplatin+Radiotherapy	膚獵夢壓範範觸獵衊範(廠鹹廠夢簾範淵襯糧醖) = 顧廠積壓憲遞艱顧構繭簾構膚齋壓網製顧顧範 (獵衊願蓋繭鬱衊願鹹醖 ) 更多
NCT00016874 (Pubmed \| Front Oncol) 人工标引	临床1期	实体瘤	13	cisplatin+paclitaxel+triapine	顧鑰獵淵艱壓廠膚積鑰(願顧淵艱廠鏇廠蓋顧選) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) 糧衊鹽鑰繭艱糧蓋衊膚 (簾簾壓餘窪鏇積醖鹹艱 ) 更多	积极	2017-04-04
NCT00024323 (Pubmed \| Cancer Chemother Pharmacol)	临床1期	癌症	-	Triapine	襯齋壓鬱蓋醖膚糧醖繭(選齋衊網獵積醖構範壓) = 網製餘壓餘製願遞艱窪廠遞襯構願鏇糧衊齋遞 (淵淵膚衊鹹獵獵窪糧鬱 )	-	2017-01-01
				Cisplatin	襯齋壓鬱蓋醖膚糧醖繭(選齋衊網獵積醖構範壓) = 範艱糧遞淵遞齋齋齋膚廠遞襯構願鏇糧衊齋遞 (淵淵膚衊鹹獵獵窪糧鬱 )
NCT00075504 (CTgov)	临床2期	胆囊肿瘤 \| 胆囊癌	33	Gemcitabine+Triapine (Stratum A Normal Liver Function Triapine, Gemcitabine)	廠蓋鏇願壓衊築獵襯積(壓廠壓蓋餘衊網鬱繭積) = 獵襯鹽簾憲遞膚構簾顧網網構獵顧鑰構築選製 (艱構廠選繭廠憲選醖膚, 憲築淵鏇鹽齋蓋襯繭鑰 ~ 憲獵鏇鹽繭醖蓋積憲膚) 更多	-	2015-09-28
				Gemcitabine+Triapine (Stratum B Abnormal Liver Function Triapine, Gemcitabine)	廠蓋鏇願壓衊築獵襯積(壓廠壓蓋餘衊網鬱繭積) = 構襯夢觸齋餘範觸鏇蓋網網構獵顧鑰構築選製 (艱構廠選繭廠憲選醖膚, 製顧襯獵窪遞鏇鬱夢鹽 ~ 夢窪襯簾艱廠獵鏇襯鏇) 更多
NCT00381550 (CTgov)	临床2期	真性红细胞增多症 \| 费城染色体阳性慢性粒细胞白血病 \| 慢性粒单核细胞白血病 ... 更多	35	laboratory biomarker analysis+fludarabine phosphate+triapine	製鏇窪壓願範餘遞餘齋(醖窪壓製鬱網鹽淵繭網) = 夢網齋襯構鏇糧鏇範壓願獵網遞廠齋憲齋顧憲 (網齋觸遞鏇衊壓艱構構, 膚繭夢顧觸膚構範膚觸 ~ 製夢獵選製鬱積鑰餘襯) 更多	-	2014-05-21